通用型CAR-T体外清除类风湿关节炎患者自身反应性B细胞
该概念验证研究构建表达固定抗FITC CAR的通用型CAR-T细胞,结合FITC标记的瓜氨酸化肽表位,体外特异性杀伤识别这些抗原的自身反应性B细胞。抗FITC CAR-T细胞的细胞毒作用依赖肽的存在且呈剂量依赖性,为RA精准定制治疗提供方向。
要点
- 抗FITC CAR-T联合FITC标记瓜氨酸化肽可体外特异性清除RA自身反应性B细胞。
- 杀伤作用依赖肽存在并呈剂量依赖性。
- 该通用型CAR-T策略有望用于RA及其他系统性自身免疫病。
核心结论
- 抗FITC CAR-T细胞联合FITC标记瓜氨酸化肽表位可体外特异性清除RA患者自身反应性B细胞,为精准定制治疗提供方向。
研究设计与样本
- 概念验证研究,选择瓜氨酸化波形蛋白、II型胶原、纤维蛋白原、tenascin-C来源的四个瓜氨酸化肽表位及环瓜氨酸肽-1作为靶向配体,构建表达固定抗FITC CAR的通用型CAR-T细胞。
主要发现
- 抗FITC CAR-T细胞经相应FITC标记瓜氨酸化肽表位识别,可特异性重定向并杀伤用抗原肽免疫产生的杂交瘤细胞及RA患者自身反应性B细胞亚群。
- CAR-T细胞的细胞毒作用依赖肽的存在,并呈剂量依赖性。
临床怎么用
- 该体外概念验证策略提示可通过通用型CAR-T联合标记肽表位选择性清除RA自身反应性B细胞,尚需进一步临床验证。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Autoreactive B cells play a crucial role in the pathogenesis of rheumatoid arthritis (RA), and B cell-depleting therapies using an antibodies, such as rituximab, have been suggested to be effective in RA treatment. However, transient B cell depletion with rituximab is associated with significant safety challenges related to global suppression of the immune system and thus increases the risks of infection and cancer development. To address selective and persistent issues associated with RA therapy, we developed a customised therapeutic strategy employing universal antifluorescein isothiocyanate (FITC) chimeric antigen receptor T cells (CAR-T cells) combined with FITC-labelled antigenic peptide epitopes to eliminate autoreactive B cell subsets recognising these antigens in RA. METHODS: For a proof-of-concept study, four citrullinated peptide epitopes derived from citrullinated autoantigens, namely, citrullinated vimentin, citrullinated type II collagen, citrullinated fibrinogen and tenascin-C, and a cyclocitrulline peptide-1 were selected as ligands for targeting autoreactive B cells; Engineered T cells expressing a fixed anti-FITC CAR were constructed and applied as a universal CAR-T cell system to specifically eliminate these protein-specific autoreactive B cells via recognition of the aforementioned FITC-labelled autoantigenic peptide epitopes. RESULTS: We demonstrated that anti-FITC CAR-T cells could be specifically redirected and kill hybridoma cells generated by immunisation with antigenic peptides, and autoreactive B cell subsets from RA patients via recognition of corresponding FITC-labelled citrullinated peptide epitopes. Additionally, the cytotoxicity of the CAR-T cells was dependent on the presence of the peptides and occurred in a dose-dependent manner. CONCLUSIONS: The approach described here provides a direction for precise, customised approaches to treat RA and can likely be applied to other systemic autoimmune diseases.
引用
- Zhang B, Wang Y, Yuan Y, et al. In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells. Ann Rheum Dis. 2020. PMID: 32998865. doi:10.1136/annrheumdis-2020-217844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。